Key statistics dashboard for NuCana plc (NCNA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform.
Stock Data
| Price | $1.30 |
| Market Cap | $8M |
| Enterprise Value | -$12.8M |
| Beta | 1.80 |
| Exchange | NASDAQ |
| Country | GB |
Valuation Multiples
| P/E Ratio | -0.32 |
| Price / Book | 0.20 |
| P/S | 0.00 |
| EV/EBITDA | 0.89 |
| EV/Sales | 0.00 |
| EV/FCF | 2.49 |
| P/FCF | -1.14 |
| Earnings Yield | -239.10% |
| FCF Yield | -87.32% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -41.95% |
| Return on Assets | -37.96% |
| Return on Invested Capital | -56.59% |
| Return on Capital Employed | -63.87% |
Financial Health
| Current Ratio | 4.73 |
| Quick Ratio | 4.73 |
| Cash Ratio | 4.04 |
| Debt / Equity | 0.03 |
| Debt / Assets | 2.61% |
| Net Debt / EBITDA | 1.30 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -12.10 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 4.81 |
| Cash per share | 4.63 |
| FCF per share | -1.23 |
| Tangible Book Value per share | 4.29 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.88 |
Related companies: CASI · CLGN · CLSD · ENLV · GDTC · LSTA · MTVA
Explore sector: Healthcare · Biotechnology
More sections of NCNA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks